Intensity Therapeutics(NASDAQ:INTS) 
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon,...
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.89
H 1.99
L 1.81
C 1.93
V 27,032
10EMA 1.93
20EMA 1.93
60EMA 1.93
120EMA 1.93
250EMA 1.93